As federal coverage expands, private insurers typically follow suit, offering: Broader formulary inclusion Lower copays Fewer preauthorization requirements Better coverage for weight-loss indications For many Westport households, especially those juggling high insurance premiums, this could significantly reduce financial strain
Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Thats a completely different clinical outcome
Key Takeaways Side effects are common with GLP-1 therapy but often manageable with proactive support
[DOI] [PMC free article] [PubMed] [Google Scholar] 10.Lisco G., Bartolomeo N., De Tullio A., De Pergola G., Guastamacchia E., Jirillo E., Piazzolla G., Triggiani V., Giagulli V.A